ReNeuron Group plc (RNUGF)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 9.64 Million GBP | -44.32% |
| 2022 | 17.32 Million GBP | -31.67% |
| 2021 | 25.35 Million GBP | 24.42% |
| 2020 | 20.37 Million GBP | -33.94% |
| 2019 | 30.84 Million GBP | -27.62% |
| 2018 | 42.61 Million GBP | -27.59% |
| 2017 | 58.86 Million GBP | -18.09% |
| 2016 | 71.85 Million GBP | 346.68% |
| 2015 | 16.08 Million GBP | -33.3% |
| 2014 | 24.11 Million GBP | 287.64% |
| 2013 | 6.22 Million GBP | -7.99% |
| 2012 | 6.76 Million GBP | -45.22% |
| 2011 | 12.34 Million GBP | 51.95% |
| 2010 | 8.12 Million GBP | 27.82% |
| 2009 | 6.35 Million GBP | -18.1% |
| 2008 | 7.75 Million GBP | -29.44% |
| 2007 | 10.99 Million GBP | 84.87% |
| 2006 | 5.94 Million GBP | 617.49% |
| 2005 | 829 Thousand GBP | -71.16% |
| 2004 | 2.87 Million GBP | -65.65% |
| 2003 | 8.36 Million GBP | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 6.42 Million GBP | -33.41% |
| 2024 Q2 | 6.42 Million GBP | 0.0% |
| 2023 Q1 | 13.82 Million GBP | -20.18% |
| 2023 Q2 | 13.82 Million GBP | 0.0% |
| 2023 Q3 | 9.64 Million GBP | -30.25% |
| 2023 FY | 9.64 Million GBP | -44.32% |
| 2023 Q4 | 9.64 Million GBP | 0.0% |
| 2022 Q2 | 21.43 Million GBP | 0.0% |
| 2022 Q3 | 17.32 Million GBP | -19.18% |
| 2022 FY | 17.32 Million GBP | -31.67% |
| 2022 Q1 | 21.43 Million GBP | -15.45% |
| 2022 Q4 | 17.32 Million GBP | 0.0% |
| 2021 Q1 | 15.41 Million GBP | -24.37% |
| 2021 FY | 25.35 Million GBP | 24.42% |
| 2021 Q4 | 25.35 Million GBP | 0.0% |
| 2021 Q3 | 25.35 Million GBP | 64.51% |
| 2021 Q2 | 15.41 Million GBP | 0.0% |
| 2020 Q2 | 28.21 Million GBP | 0.0% |
| 2020 Q1 | 28.21 Million GBP | -8.55% |
| 2020 Q4 | 20.37 Million GBP | 0.0% |
| 2020 FY | 20.37 Million GBP | -33.94% |
| 2020 Q3 | 20.37 Million GBP | -27.77% |
| 2019 FY | 30.84 Million GBP | -27.62% |
| 2019 Q1 | 37.11 Million GBP | -12.92% |
| 2019 Q2 | 37.11 Million GBP | 0.0% |
| 2019 Q3 | 31.51 Million GBP | -15.09% |
| 2019 Q4 | 30.84 Million GBP | -2.1% |
| 2018 Q2 | 50.49 Million GBP | 0.0% |
| 2018 FY | 42.61 Million GBP | -27.59% |
| 2018 Q1 | 50.49 Million GBP | -14.21% |
| 2018 Q4 | 42.61 Million GBP | 0.0% |
| 2018 Q3 | 42.61 Million GBP | -15.6% |
| 2017 FY | 58.86 Million GBP | -18.09% |
| 2017 Q4 | 58.86 Million GBP | 0.0% |
| 2017 Q3 | 58.86 Million GBP | -9.52% |
| 2017 Q2 | 65.05 Million GBP | 0.0% |
| 2017 Q1 | 65.05 Million GBP | -9.47% |
| 2016 Q2 | 77.15 Million GBP | 0.0% |
| 2016 FY | 71.85 Million GBP | 346.68% |
| 2016 Q1 | 77.15 Million GBP | 379.6% |
| 2016 Q3 | 71.85 Million GBP | -6.86% |
| 2016 Q4 | 71.85 Million GBP | 0.0% |
| 2015 FY | 16.08 Million GBP | -33.3% |
| 2015 Q1 | 19.99 Million GBP | -17.08% |
| 2015 Q4 | 16.08 Million GBP | 0.0% |
| 2015 Q3 | 16.08 Million GBP | -19.56% |
| 2015 Q2 | 19.99 Million GBP | 0.0% |
| 2014 Q2 | 26.89 Million GBP | 0.0% |
| 2014 FY | 24.11 Million GBP | 287.64% |
| 2014 Q4 | 24.11 Million GBP | 0.0% |
| 2014 Q3 | 24.11 Million GBP | -10.32% |
| 2014 Q1 | 26.89 Million GBP | 332.27% |
| 2013 Q2 | 9.28 Million GBP | 0.0% |
| 2013 Q3 | 6.22 Million GBP | -33.01% |
| 2013 FY | 6.22 Million GBP | -7.99% |
| 2013 Q4 | 6.22 Million GBP | 0.0% |
| 2012 Q4 | 6.76 Million GBP | 0.0% |
| 2012 Q2 | 9.09 Million GBP | 0.0% |
| 2012 FY | 6.76 Million GBP | -45.22% |
| 2011 Q2 | 6.33 Million GBP | 0.0% |
| 2011 FY | 12.34 Million GBP | 51.95% |
| 2011 Q4 | 12.34 Million GBP | 0.0% |
| 2010 FY | 8.12 Million GBP | 27.82% |
| 2010 Q4 | 8.12 Million GBP | 0.0% |
| 2010 Q2 | 7.27 Million GBP | 0.0% |
| 2009 Q4 | 6.35 Million GBP | 0.0% |
| 2009 Q2 | 5.73 Million GBP | 0.0% |
| 2009 FY | 6.35 Million GBP | -18.1% |
| 2008 Q4 | 7.75 Million GBP | 0.0% |
| 2008 Q2 | 11.43 Million GBP | 0.0% |
| 2008 FY | 7.75 Million GBP | -29.44% |
| 2007 Q4 | 10.99 Million GBP | 0.0% |
| 2007 Q2 | 5.87 Million GBP | 0.0% |
| 2007 FY | 10.99 Million GBP | 84.87% |
| 2006 FY | 5.94 Million GBP | 617.49% |
| 2006 Q2 | 8.05 Million GBP | 0.0% |
| 2006 Q4 | 5.94 Million GBP | 0.0% |
| 2005 Q4 | 829 Thousand GBP | 0.0% |
| 2005 FY | 829 Thousand GBP | -71.16% |
| 2005 Q2 | 1.23 Million GBP | 0.0% |
| 2004 FY | 2.87 Million GBP | -65.65% |
| 2003 FY | 8.36 Million GBP | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Capstone Therapeutics Corp. | 52.7 Million USD | 81.699% |
| Skye Bioscience, Inc. | 11.94 Million USD | 19.224% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 92.593% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -1646.903% |
| Qrons Inc. | 420.00 USD | -2296328.571% |
| Adynxx, Inc. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 14.56 Million USD | 33.758% |
| CSL Limited | 38.02 Billion USD | 99.975% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 8.613% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -392.547% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -2627.527% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 65.485% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -1907.046% |
| Rebus Holdings, Inc. | 5000.00 USD | -192800.0% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -417432.468% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -1151.551% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -1302.938% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 75.172% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -33.592% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -12531.951% |
| SQZ Biotechnologies Company | 107.18 Million USD | 91.002% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -573.518% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -13228.266% |
| Mesoblast Limited | 667.9 Million USD | 98.556% |
| Marizyme, Inc. | 22.01 Million USD | 56.189% |
| Genus plc | 1.02 Billion USD | 99.063% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -610.051% |
| Pharming Group N.V. | 462.85 Million USD | 97.916% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -191.125% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -1832.715% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -1438.278% |
| ContraFect Corporation | 20.67 Million USD | 53.358% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -2370.758% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -2423.7% |
| IMV Inc. | 31.33 Million USD | 69.219% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -132.633% |
| MultiCell Technologies, Inc. | 126.22 USD | -7641319.743% |
| ONE Bio Corp. | 70.08 Million USD | 86.238% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -926.403% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 92.495% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | -2134.118% |
| Q BioMed Inc. | 3.51 Million USD | -174.355% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 72.583% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -3591.485% |
| Biomind Labs Inc. | 73.81 Thousand USD | -12965.742% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 97.839% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -565.704% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 67.866% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -251.195% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -270.506% |
| GB Sciences, Inc. | 103.44 Thousand USD | -9224.066% |
| Alpha Cognition Inc. | 2.45 Million USD | -293.325% |
| HST Global, Inc. | 1526.00 USD | -631944.561% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -876.247% |
| Halberd Corporation | 10.13 Thousand USD | -95102.843% |
| Enzolytics Inc. | 361.7 Million USD | 97.333% |
| Agentix Corp. | 261.39 Thousand USD | -3589.86% |
| Resverlogix Corp. | 8.11 Million USD | -18.854% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -413.611% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.788% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 79.781% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -1407.842% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -42237.913% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | -7.776% |
| AVAX Technologies, Inc. | 7.37 Million USD | -30.741% |
| Zenith Capital Corp. | 7410.00 USD | -130061.943% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.715% |
| Ember Therapeutics, Inc. | 184.00 USD | -5241747.826% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -2897.147% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -3590.256% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -939.376% |
| Kadimastem Ltd | 2.3 Million USD | -318.605% |
| Helix BioMedix, Inc. | 3.02 Million USD | -218.834% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -16793.194% |
| LadRx Corporation | 2.3 Million USD | -317.916% |
| Cell Source, Inc. | 195.17 Thousand USD | -4841.82% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -2627.527% |
| NovAccess Global Inc. | 62.24 Thousand USD | -15394.474% |
| Affymax, Inc. | 7.44 Million USD | -29.585% |
| Itoco Inc. | 1.4 Million USD | -588.893% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -9982.9% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -8999.057% |
| Mobile Lads Corp. | 52.00 USD | -18547976.923% |
| CytoDyn Inc. | 11.13 Million USD | 13.389% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -6646.076% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -53842.953% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -2402.134% |
| SYBLEU INC | 330.46 Thousand USD | -2818.588% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -2255.76% |
| International Stem Cell Corporation | 5.39 Million USD | -78.942% |
| Bioxytran, Inc. | 137.63 Thousand USD | -6907.512% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 35.708% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 41.824% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -12108.861% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -1015.445% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -28.309% |
| Neutra Corp. | 2851.00 USD | -338202.35% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 70.237% |
| PureTech Health plc | 693.97 Million USD | 98.61% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -19.501% |
| IXICO plc | 15.84 Million USD | 39.125% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -16.457% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 90.665% |
| CSL Limited | 38.02 Billion USD | 99.975% |
| Cellectis S.A. | 333.99 Million USD | 97.112% |